ICRAPAIN 2026 Brings 600+ Pain Professionals to Kolkata, Highlights Advances in Pain Biologics and Regenerative Medicine

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

Landmark 10th international conference combines scientific exchange, research and hands-on learning, with emerging therapies for knee osteoarthritis among key areas of discussion

KOLKATA, INDIA, September 2026: The 10th International Conference on Recent Advances in Pain (ICRAPAIN 2026) concluded successfully in Kolkata, bringing together more than 600 pain professionals for three days of scientific lectures, panel discussions, research presentations, masterclasses and practical education.

Held from September 3–6, 2026, the conference was organized by Daradia Pain Foundation with Daradia: The Pain Clinic, Kolkata , under the theme “ From Evidence to Practice: Shaping the Future of Pain Medicine .”

The scientific programme covered a broad spectrum of contemporary pain medicine, including musculoskeletal ultrasound, radiofrequency procedures, neuromodulation, spine interventions, neuropathic and nociplastic pain, cancer pain, artificial intelligence and Pain Biologics and regenerative medicine .

ICRAPAIN 2026 also placed strong emphasis on research, with 52 scientific abstracts , including 42 delegate submissions and 10 faculty abstracts. The conference encouraged clinicians and young researchers to move beyond procedural learning toward evidence-based clinical reasoning, patient selection and scientific enquiry.

Post-conference feedback reflected strong participant satisfaction. Among 81 respondents, both the overall conference and scientific programme received average ratings of 9.22/10 , while the Live Pain Biologics Workshop received 9.63/10 . A detailed report on the scientific programme, participant feedback and highlights is available in the ICRAPAIN 2026 Conference Report and Feedback .

One of the areas attracting considerable scientific interest was the evolving role of Pain Biologics and non-surgical treatment of knee osteoarthritis .

Lectures and discussions explored Platelet-Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), mesenchymal stromal cells and phenotype-based approaches to osteoarthritis management.

The scientific programme also discussed Ciplostem , an allogeneic bone-marrow-derived mesenchymal stromal cell therapy developed by Stempeutics Research and marketed in India by Cipla . Ciplostem has received approval from the Drugs Controller General of India (DCGI) for selected patients with Grade II and Grade III knee osteoarthritis.

The discussion focused on evidence, appropriate patient selection, joint preservation and the potential role of regenerative therapies within a broader strategy for the non-surgical management of knee osteoarthritis .

Ahead of the main conference, a dedicated pre-conference Live Pain Biologics Workshop provided practical exposure to regenerative interventions.